4,130 reports of this reaction
14.8% of all LEDIPASVIR AND SOFOSBUVIR reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for LEDIPASVIR AND SOFOSBUVIR, manufactured by Gilead Sciences, Inc. There are 4,130 FDA adverse event reports linking LEDIPASVIR AND SOFOSBUVIR to FATIGUE. This represents approximately 14.8% of all 27,933 adverse event reports for this drug.
Patients taking LEDIPASVIR AND SOFOSBUVIR who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a frequently reported adverse event for LEDIPASVIR AND SOFOSBUVIR, accounting for a significant proportion of all reports.
In addition to fatigue, the following adverse reactions have been reported for LEDIPASVIR AND SOFOSBUVIR:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 4,130 FDA reports for LEDIPASVIR AND SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 14.8% of all adverse event reports for LEDIPASVIR AND SOFOSBUVIR, making it one of the most commonly reported side effect.
If you experience fatigue while taking LEDIPASVIR AND SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.